Surufatinib

索凡替尼

Report date: 2026/03/31 20:00:21
NME

Base Information

Drug NameSurufatinib
Drug Alias NameSulfatinibSuofantiniSufatinibSoventinibSovalteinib +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionFibroblast growth factor receptor 1 antagonistsColony stimulating factor 1 receptor inhibitorsVascular endothelial growth factor receptor antagonists
TargetsFibroblast growth factor receptor 1Colony stimulating factor 1 receptorVascular endothelial growth factor receptor
Therapy Area/IndicationsPancreatic neuroendocrine tumors (pNET)Solid tumoursRenal Insufficiency +[16] 
Global Approved IndicationsNeuroendocrine Tumors
Approved Indications in ChinaNeuroendocrine Tumors
Original Approved Country/TerritoryMainland China
Original Approved Date2020/12/29
Country/TerritoryUnited StatesNorwayItaly +[9] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesHutchison Medipharma Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesHutchmed (Hong Kong) LtdFudan UniversitySun Yat-Sen University +[5] 
Inactive CompaniesPeking University
Active IndicationsPancreatic neuroendocrine tumors (pNET)Solid tumoursRenal Insufficiency +[13] 
Inactive IndicationsBile Duct NeoplasmsBiliary Tract NeoplasmsNeoplasms

Other Information

ATC CodeL01XX
Related LinksN/A